New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

Two U.S. Food and Drug Administration (FDA)-approved drugs for treating prostate cancer may also be effective against acute ...

We transformed care for advanced prostate cancer, by validating inhibitors of androgen production as an effective cancer ...

Scientists have uncovered a critical weakness in prostate cancer’s defences. The disease relies on two enzymes, PDIA1 and ...

Researchers have discovered that prostate cancer depends on two key enzymes, PDIA1 and PDIA5, to survive and resist therapy.

Zydus Lifesciences has secured USFDA approval for its Leuprolide Acetate injection, a treatment for advanced prostatic cancer.

Final draft guidance on NHS use of the drug marks a "significant shift" from NICE's 2021 decision on the drug as a first-line treatment for newly diagnosed, advanced HSPC in combination with androgen ...

The FDA-approved drug Pluvicto offers hope for advanced prostate cancer patients, but access barriers remain despite proven ...

A groundbreaking new study has found that a combination of two drugs can boost survival rates in prostate cancer patients by ...

A groundbreaking study reveals that combining two drugs significantly boosts survival for men with high-risk, recurring ...